Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Masayuki
Okahashi, Aya
Okuyama, Kotoba
Hiraishi, Naomi
Morioka, Ichiro
-
Funding
Funding for this research was provided by:
msd k.k.
- License Information
-
More Information
Article History
Received: 29 July 2021
Accepted: 23 October 2021
First Online: 21 December 2021
Declarations
:
: The study protocol was approved by the ethics review board of the Medical Corporation Toukeikai Kitamachi Clinic, and all participants provided electronic informed consent.
: Not applicable.
: MK, KO, and NH are employees of MSD K.K., Tokyo, Japan, a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA., and may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, N.J., USA. AO has received personal fees from AbbVie, LLC outside of the submitted work. IM has received grants from Japan Blood Product Organization, Eli Lilly Japan K.K., AbbVie LLC, Teijin Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Shionogi Co., Ltd., and JCR Pharmaceuticals Co., Ltd.; lecture fees from MSD Co., Ltd., Pfizer Japan, Inc., Novo Nordisk Pharma Ltd., Shionogi Co., Ltd., AbbVie LLC, Shino-test Corp., and Atom Medical Corp outside of the submitted work.
